Twelve months after releasing a roadmap to shift away from animal testing requirements, the FDA has declared mission ...

Just a few years ago, Daniel Chen, M.D., Ph.D., was spending his spare time in his backyard, sketching out designs for new ...

Eli Lilly's acquisition spree shows no sign of stalling, although the Big Pharma is keeping the terms of its latest buy ...

After a recent streak of buyouts by some of Big Pharma's serial acquirers, Belgium's UCB is getting | The agreement fulfills ...

Kailera Therapeutics appears to have set a new benchmark for biotech IPOs with an upsized $625 million offering to fund its ...

The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s ...

Following its recently announced partnership with Novo Nordisk, OpenAI is introducing a new reasoning model, GPT-Rosalind, to ...

The FDA’s former top drug regulator Richard Pazdur, M.D., has lamented the loss of expert voices at the agency. | Asked by ...

The former leaders of SpringWorks Therapeutics are back with a new biotech venture that is already buzzing from a $300 ...

Aligos Therapeutics has secured a $25 million cash infusion in return for selling the China rights to its phase 2-stage ...

After its bet on a rare eye disease gene therapy ended in a phase 3 fail last year, Johnson & Johnson is now returning the ...

To Ocugen CEO Shankar Musunuri, Ph.D., most gene therapy biotechs today lack vision. | Many gene therapy outfits focus on ...